NASDAQ:NRSN NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis $3.58 -0.24 (-6.28%) Closing price 10/8/2026 04:00 PM EasternExtended Trading$3.61 +0.03 (+0.84%) As of 05:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About NeuroSense Therapeutics Stock (NASDAQ:NRSN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NRSN alerts:Sign Up Key Stats Today's Range$3.56▼$3.9050-Day Range$3.58▼$10.8452-Week Range$3.56▼$26.64Volume15,840 shsAverage Volume23,480 shsMarket Capitalization$6.80 millionP/E RatioN/ADividend YieldN/APrice Target$170.00Consensus RatingModerate Buy Company Overview NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research is centered on therapeutic approaches intended to address multiple disease mechanisms, including neuroinflammation, abnormal RNA regulation and other biological processes associated with the progression of neurological disorders. Its leading product candidate is PrimeC, an oral combination formulation of ciprofloxacin and celecoxib being developed primarily for amyotrophic lateral sclerosis (ALS). NeuroSense has evaluated PrimeC in clinical studies designed to assess its safety and potential effects on disease progression, and the candidate has received regulatory designations intended to support its development for ALS. The company has also explored applications of its platform in other neurodegenerative conditions, including Alzheimer’s disease. NeuroSense was established in Israel and conducts its development activities through collaborations and clinical programs serving international markets. The company is led by Chief Executive Officer Alon Ben-Noon. As a biotechnology company, NeuroSense’s products remain in the development stage and are subject to further clinical, regulatory and commercial evaluation.AI Generated. May Contain Errors. Read More NeuroSense Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreNRSN MarketRank™: NeuroSense Therapeutics scored higher than 57% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingNeuroSense Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNeuroSense Therapeutics has a consensus price target of $170.00, representing about 4,648.6% upside from its current price of $3.58.Amount of Analyst CoverageNeuroSense Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about NeuroSense Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for NeuroSense Therapeutics are expected to decrease in the coming year, from ($6.62) to ($11.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroSense Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroSense Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about NeuroSense Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.78% of the float of NeuroSense Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeuroSense Therapeutics has a short interest ratio ("days to cover") of 0.95, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroSense Therapeutics has recently decreased by 91.85%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuroSense Therapeutics does not currently pay a dividend.Dividend GrowthNeuroSense Therapeutics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.14 News SentimentNeuroSense Therapeutics has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for NeuroSense Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for NRSN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added NeuroSense Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NeuroSense Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders27.40% of the stock of NeuroSense Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions1.04% of the stock of NeuroSense Therapeutics is held by institutions.Read more about NeuroSense Therapeutics' insider trading history. Receive NRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRSN Stock News HeadlinesNeurosense Therapeutics Receives Nasdaq Listing Compliance NoticeOctober 3, 2026 | finance.yahoo.comNeuroSense Provides Update on Nasdaq Listing ComplianceOctober 2, 2026 | prnewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)NeuroSense Therapeutics consensus price target increased by 1,507.27% to $112.71October 2, 2026 | msn.comNeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Stock Has Average Target Price of $170.00 According to BrokeragesOctober 1, 2026 | americanbankingnews.comWhat is HC Wainwright's Estimate for NRSN FY2026 Earnings?September 30, 2026 | americanbankingnews.comNeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities ConferenceSeptember 28, 2026 | prnewswire.comNeuroSense H1 Net Loss Narrows; Targets December NDS Filing For PrimeC In ALSSeptember 28, 2026 | rttnews.comSee More Headlines NRSN Stock Analysis - Frequently Asked Questions How have NRSN shares performed this year? NeuroSense Therapeutics' stock was trading at $15.38 at the start of the year. Since then, NRSN stock has decreased by 76.7% and is now trading at $3.58. How were NeuroSense Therapeutics' earnings last quarter? NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) issued its quarterly earnings results on Monday, April, 7th. The company reported ($1.20) EPS for the quarter, topping analysts' consensus estimates of ($2.40) by $1.20. When did NeuroSense Therapeutics' stock split? NeuroSense Therapeutics's stock reverse split on Monday, September 14th 2026.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, September 13th 2026. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did NeuroSense Therapeutics IPO? NeuroSense Therapeutics (NRSN) raised $13 million in an initial public offering on Wednesday, December 8th 2021. The company issued 2,000,000 shares at $6.00-$7.00 per share. How do I buy shares of NeuroSense Therapeutics? Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NeuroSense Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroSense Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Abbott Laboratories (ABT) and Energy Select Sector SPDR Fund (XLE). Company Calendar Last Earnings4/07/2025Today10/08/2026Next Earnings (Estimated)12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (9m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 NRSN's financial health is in the Red zone, according to TradeSmith. NRSN has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NRSN CIK1875091 Webwww.neurosense-tx.com Phone972-9799-6183FaxN/AEmployees16Year FoundedN/APrice Target and Rating Average Price Target for NeuroSense Therapeutics$170.00 High Price Target$280.00 Low Price Target$60.00 Potential Upside/Downside+4,648.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.28 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.96) per share Price / Book-3.73Miscellaneous Outstanding Shares1,900,000Free Float1,377,000Market Cap$6.80 million OptionableNot Optionable Beta1.66 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:NRSN) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NRSN Stock Alerts